Vaccines · 2026
Feasibility and Safety of Autologous Dendritic Cell Vaccination Combined with Radio-Chemotherapy in Newly Diagnosed Glioblastoma: A Retrospective Single-Center Series.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Esparragosa Vázquez Inés, López-Díaz de Cerio Ascensión, Inoges Susana, Aristu Javier, Domínguez Pablo, García-Eulate Reyes, Calvo-Imirizaldu Marta, Arbizu Javier, Rodríguez-Ruiz María E, Irimia Pablo, Alonso Marta M, Prósper Felipe, Díez-Valle Ricardo, Gállego Pérez-Larraya Jaime
Аннотация
BACKGROUND: The prognosis of glioblastoma (GBM) patients remains poor. Dendritic cell (DC) vaccination has been investigated as an immunotherapy option, mainly in early-phase clinical studies. Herein, we report the feasibility, safety, and descriptive clinical and radiological outcomes of a retrospective series of newly diagnosed GBM patients treated with standard radio-chemotherapy and autologous DC vaccination as compassionate use.
METHODS: We retrospectively reviewed the medical and radiological records of patients with newly diagnosed GBM who received autologous tumor lysate-pulsed DC vaccination in addition to standard-of-care treatment at a tertiary academic center between 2009 and 2017. Clinical data, treatment characteristics, adverse events, survival outcomes, and radiological responses were collected and analyzed descriptively.
RESULTS: Twenty-four patients were included. All patients underwent surgical resection and were further treated with autologous tumor lysate-DC vaccination and standard radio-chemotherapy. Histology of GBM was confirmed in all patients. The first vaccine was administered in 75% of patients after a median of 21 days (range: 6-30 days) following surgery and prior to radiotherapy initiation. DC vaccination was continued following radiotherapy at specific time points, with no observed significant adverse events. Median OS was 21.1 months (95% CI, 27.9-75.0 months), and median PFS was 10.3 months (95% CI, 15.6-26.6 months). Presence of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation was associated with longer survival and higher 12-month PFS rates, consistent with its established prognostic value. Radiological responses were retrospectively assessed according to RANO and RANO 2.0 criteria.
CONCLUSIONS: In this retrospective single-center series, autologous DC vaccination administered as compassionate use in combination with standard radio-chemotherapy was feasible and safe in routine clinical practice. Survival and radiological outcomes are reported descriptively and should be interpreted with caution given the absence of a control cohort. These findings support further prospective controlled studies to properly assess the clinical role of DC vaccination in newly diagnosed GBM.
METHODS: We retrospectively reviewed the medical and radiological records of patients with newly diagnosed GBM who received autologous tumor lysate-pulsed DC vaccination in addition to standard-of-care treatment at a tertiary academic center between 2009 and 2017. Clinical data, treatment characteristics, adverse events, survival outcomes, and radiological responses were collected and analyzed descriptively.
RESULTS: Twenty-four patients were included. All patients underwent surgical resection and were further treated with autologous tumor lysate-DC vaccination and standard radio-chemotherapy. Histology of GBM was confirmed in all patients. The first vaccine was administered in 75% of patients after a median of 21 days (range: 6-30 days) following surgery and prior to radiotherapy initiation. DC vaccination was continued following radiotherapy at specific time points, with no observed significant adverse events. Median OS was 21.1 months (95% CI, 27.9-75.0 months), and median PFS was 10.3 months (95% CI, 15.6-26.6 months). Presence of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation was associated with longer survival and higher 12-month PFS rates, consistent with its established prognostic value. Radiological responses were retrospectively assessed according to RANO and RANO 2.0 criteria.
CONCLUSIONS: In this retrospective single-center series, autologous DC vaccination administered as compassionate use in combination with standard radio-chemotherapy was feasible and safe in routine clinical practice. Survival and radiological outcomes are reported descriptively and should be interpreted with caution given the absence of a control cohort. These findings support further prospective controlled studies to properly assess the clinical role of DC vaccination in newly diagnosed GBM.